UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 8, 2021

 

Streamline Health Solutions, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   0-28132   31-1455414

(State or other jurisdiction

of incorporation)

  (Commission
File Number)
  (I.R.S. Employer
Identification No.)

 

11800 Amber Park Dr., Suite 125

Alpharetta, GA 30009

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (888) 997-8732

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock, $0.01 par value   STRM   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 2.02 Results of Operations and Financial Condition.

 

On September 8, 2021, Streamline Health Solutions, Inc. (the “Company”) issued a press release announcing second quarter fiscal 2021 financial results. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

The information contained in this Item 2.02, as well as Exhibit 99.1 referenced herein, is being “furnished” and, as such, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended, unless the Company expressly so incorporates such information by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

EXHIBIT

NUMBER

  DESCRIPTION
     
99.1   Press release, dated September 8, 2021, regarding Second Quarter Fiscal 2021 Financial Results.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  STREAMLINE HEALTH SOLUTIONS, INC.
   
Date: September 8, 2021 By:  /s/ Thomas J. Gibson
    Thomas J. Gibson
    Chief Financial Officer

 

 
 

 

 

Exhibit 99.1

 

 

 

Streamline Health® Reports Second Quarter 2021 Financial Results

 

Second quarter 2021 Revenues of $2.9 million; ($0.1 million) Net Loss; ($0.8 million) Adjusted EBITDA

 

Atlanta, GA / Wire / September 8, 2021 / Streamline Health Solutions, Inc. (NASDAQ: STRM) (“Streamline”), provider of the eValuator™ Revenue Integrity Program to help healthcare providers proactively address revenue leakage and compliance exposure, today announced financial results for the second quarter of fiscal year 2021, which ended July 31, 2021.

 

Total revenues for the second quarter of fiscal 2021 were $2.9 million, consistent with the prior year period. SaaS revenue grew approximately 59%, compared to the same quarter a year ago. The consistent revenue volume during the quarter was the result of higher revenue from SaaS offset by lower revenue from professional services, software licenses and maintenance and support. Recurring revenue comprised 84% of second quarter fiscal 2021 revenue compared to 71% of second quarter fiscal 2020 revenue.

 

Net loss for the second quarter of fiscal 2021 was ($0.1 million) as compared to a net loss of ($1.1 million) during the second quarter of fiscal 2020. Second quarter fiscal 2021 net loss included $11,000 of income from discontinued operations of the Company’s legacy ECM business, the sale of which closed on February 24, 2020, compared to $28,000 of income from discontinued operations during the second quarter of fiscal 2020. Income from discontinued operations was offset by a loss from continuing operations for the three months ended July 31, 2021 and 2020 of ($0.1 million) and ($1.2 million), respectively. Loss from continuing operations for the three months ended July 31, 2021 included $2.3 million of income associated with loan forgiveness.

 

Adjusted EBITDA for the second quarter of fiscal 2021 was a loss of ($0.8 million), compared to an adjusted EBITDA loss of ($0.4 million) in the second quarter of fiscal 2020.

 

“As a result of our team’s execution to restructure and position Streamline for growth, we were thrilled to enter a new chapter with our recent acquisition of Avelead. Thanks to our focus on improved sales and customer success, we are ready to capitalize on our tremendous market opportunity while maintaining strong relationships with our existing customers.” stated Tee Green, President and Chief Executive Officer, Streamline.

 

“We believe that the Delta variant of COVID has delayed our reporting of successes on the sales side, however, it has not deterred our improving the systems and processes that enable the growth we are expecting. Today, we are more capable than ever of supporting our healthcare provider customers through pre-bill revenue cycle solutions to ensure their revenue integrity and improved financial performance.”

 

 
 

 

Highlights from the second quarter ended July 31, 2021 included:

 

Revenue for the second quarter of fiscal 2021 was $2.9 million; SaaS revenue grew 11%, sequentially, compared to the first quarter of fiscal 2021;
Loss from continuing operations for the second quarter of fiscal 2021 was ($0.1 million);
Adjusted EBITDA for the second quarter of fiscal 2021 was ($0.8 million);
Total bookings (total contract value) for the second quarter of fiscal 2021 were $1.6 million.

 

Conference Call

 

The Company will conduct a conference call to review the results and to provide additional detail about its recent acquisition on Thursday, September 9, 2021 at 9:00 AM ET. Interested parties can access the call by joining the live webcast: click here to register. You can also join by phone by dialing 877-407-8291.

 

A replay of the conference call will be available from Thursday September 9, 2021 at 12:00 PM ET to Thursday, September 16, 2021 at 12:00 PM ET by dialing 877-660-6853 or 201-612-7415 with conference ID 13722259. An online replay of the presentation will also be available for six months following the presentation in the Investor Relations section of the Streamline website, www.streamlinehealth.net.

 

Non-GAAP Financial Measures

 

Streamline reports its financial results in accordance with U.S. generally accepted accounting principles (“GAAP”). Streamline’s management also evaluates and makes operating decisions using various other measures. One such measure is adjusted EBITDA, which is a non-GAAP financial measure. Streamline’s management believes that this measure provides useful supplemental information regarding the performance of Streamline’s business operations.

 

Streamline defines “adjusted EBITDA” as net earnings (loss) plus interest expense, tax expense, depreciation and amortization expense of tangible and intangible assets, stock-based compensation expense, significant non-recurring operating expenses, and transactional related expenses including: gains and losses on debt and equity conversions, associate severances and related restructuring expenses, associate inducements, and professional and advisory fees. A table illustrating this measure is included in this press release.

 

About Streamline

 

Streamline Health Solutions, Inc. (NASDAQ: STRM) is a leader in pre-bill revenue integrity solutions for healthcare providers. Our eValuator™ Revenue Integrity Program includes integrated solutions, technology-enabled services and analytics that drive compliant revenue and improved financial performance across the enterprise. We share a common calling and commitment to advance the quality of life and the quality of healthcare - for society, our clients, the communities they serve, and the individual patient. For more information, please visit our website at www.streamlinehealth.net.

 

 
 

 

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995

 

Statements made by Streamline Health Solutions, Inc. that are not historical facts are forward-looking statements that are subject to certain risks, uncertainties and important factors that could cause actual results to differ materially from those reflected in the forward-looking statements included herein. Forward-looking statements contained in this press release include, without limitation, statements regarding the Company’s growth prospects, estimates of backlog, industry trends and market growth, results of investments in sales and marketing, adjusted EBITDA, success of future products and related expectations and assumptions. These risks and uncertainties include, but are not limited to, the timing of contract negotiations and execution of contracts and the related timing of the revenue recognition related thereto, the potential cancellation of existing contracts or clients not completing projects included in the backlog, the impact of competitive solutions and pricing, solution demand and market acceptance, new solution development and enhancement of current solutions, key strategic alliances with vendors and channel partners that resell the Company’s solutions, the ability of the Company to control costs, the effects of cost-containment measures implemented by the Company, availability of solutions from third party vendors, the healthcare regulatory environment, potential changes in legislation, regulation and government funding affecting the healthcare industry, healthcare information systems budgets, availability of healthcare information systems trained personnel for implementation of new systems, as well as maintenance of legacy systems, fluctuations in operating results, effects of critical accounting policies and judgments, changes in accounting policies or procedures as may be required by the Financial Accounting Standards Board or other similar entities, changes in economic, business and market conditions impacting the healthcare industry generally and the markets in which the Company operates and nationally, the Company’s ability to maintain compliance with the terms of its credit facilities, and other risks detailed from time to time in the Streamline Health Solutions, Inc. filings with the U. S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date hereof. The Company undertakes no obligation to publicly release the results of any revision to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.

 

Contact

Jacob Goldberger

Director, Investor Relations and FP&A

303-887-9625

Jacob.goldberger@streamlinehealth.net

 

 
 

 

STREAMLINE HEALTH SOLUTIONS, INC.

CONSOLIDATED AND CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

 

   Three Months Ended   Six Months Ended 
   July 31,   July 31, 
   2021   2020   2021   2020 
Revenues:                    
Software licenses  $-   $215,000   $135,000   $215,000 
Professional services   30,000    160,000    108,000    312,000 
Audit Services   443,000    463,000    947,000    1,007,000 
Maintenance and support   1,087,000    1,228,000    2,144,000    2,486,000 
Software as a service   1,308,000    821,000    2,485,000    1,711,000 
Total revenues   2,868,000    2,887,000    5,819,000    5,731,000 
                     
Operating expenses:                    
Cost of software licenses   143,000    125,000    279,000    202,000 
Cost of professional services   261,000    269,000    475,000    510,000 
Cost of audit services   376,000    373,000    765,000    733,000 
Cost of maintenance and support   80,000    182,000    166,000    368,000 
Cost of software as a service   578,000    403,000    1,188,000    808,000 
Selling, general and administrative   2,515,000    2,284,000    5,068,000    4,576,000 
Research and development   964,000    509,000    1,941,000    1,193,000 
Non-routine costs   336,000    -    777,000    - 
Loss on exit of membership agreement   -    -    -    105,000 
Total operating expenses   5,253,000    4,145,000    10,659,000    8,495,000 
Operating loss   (2,385,000)   (1,258,000)   (4,840,000)   (2,764,000)
Other (expense) income:                    
Interest expense   (9,000)   (13,000)   (22,000)   (27,000)
Miscellaneous expense   (8,000)   (64,000)   6,000    (82,000)
Forgiveness of PPP loan and accrued interest   2,327,000    -    2,327,000    - 
Loss before income taxes   (75,000)   (1,335,000)   (2,529,000)   (2,873,000)
Income tax benefit (expense)   4,000    172,000    (5,000)   733,000 
Loss from continuing operations  $(71,000)  $(1,163,000)  $(2,534,000)  $(2,140,000)
Income from discontinued operations:                    
Gain on sale of discontinued operations   -    4,000    -    6,013,000 
Income from discontinued operations   11,000    104,000    332,000    241,000 
Income tax expense   -    (80,000)   -    (1,576,000)
Income from discontinued operations   11,000    28,000    332,000    4,678,000 
Net (loss) income  $(60,000)  $(1,135,000)  $(2,202,000)  $2,538,000 
                     
Basic Earnings per Share:                    
Continuing operations  $(0.00)  $(0.04)  $(0.06)  $(0.07)
Discontinued operations   0.00    0.00    0.01    0.16 
Net (loss) income  $(0.00)  $(0.04)  $(0.05)  $0.09 
Weighted average number of common shares - basic   41,288,709    30,026,658    39,393,333    29,897,236 
                     
Diluted Earnings per Share:                    
Continuing operations  $(0.00)  $(0.04)  $(0.06)  $(0.07)
Discontinued operations   0.00    0.00    0.01    0.15 
Net (loss) income  $(0.00)  $(0.04)  $(0.05)  $0.08 
Weighted average number of common shares – diluted   41,737,231    30,421,473    39,960,998    30,229,595 

 

 
 

 

STREAMLINE HEALTH SOLUTIONS, INC.

CONSOLIDATED AND CONDENSED BALANCE SHEETS

(Unaudited)

 

   July 31,   January 31, 
   2021   2021 
Assets          
Current assets:          
Cash and cash equivalents  $15,847,000   $2,409,000 
Accounts receivable, net   2,625,000    2,929,000 
Contract receivables   236,000    174,000 
Prepaid and other current assets   788,000    1,216,000 
Current assets from discontinued operations   181,000    587,000 
Total current assets   19,677,000    7,315,000 
           
Non-current assets:          
Property and equipment, net   76,000    104,000 
Right of use asset on operating lease   306,000    391,000 
Capitalized software development costs, net   5,667,000    5,945,000 
Intangible assets, net   393,000    624,000 
Goodwill   10,712,000    10,712,000 
Other non-current assets   1,003,000    873,000 
Long-term assets from discontinued operations   3,000    13,000 
Total non-current assets   18,160,000    18,662,000 
   $37,837,000   $25,977,000 
           
Liabilities and Stockholders’ Equity          
Current liabilities:          
Accounts payable  $363,000   $272,000 
Accrued expenses   1,324,000    908,000 
Current portion of term loan   -    1,534,000 
Deferred revenues   4,474,000    3,862,000 
Current portion of operating lease obligation   201,000    198,000 
Current liabilities from discontinued operations   283,000    595,000 
Total current liabilities   6,645,000    7,369,000 
           
Non-current liabilities:          
Term loan, net of current portion   -    767,000 
Deferred revenues, less current portion   163,000    130,000 
Operating Lease obligations, less current portion   129,000    222,000 
Total non-current liabilities   292,000    1,119,000 
Total liabilities   6,937,000    8,488,000 
           
Stockholders’ equity   30,900,000    17,489,000 
   $37,837,000   $25,977,000 

 

 
 

 

STREAMLINE HEALTH SOLUTIONS, INC.

CONSOLIDATED AND CONDENSED STATEMENT OF CASH FLOWS

(Unaudited)

 

   Six Months Ended 
   July 31, 
   2021   2020 
Cash flows from continuing operating activities:          
Loss from continuing operations  $(2,534,000)  $(2,140,000)
Depreciation   37,000    31,000 
Amortization of capitalized software development costs   984,000    651,000 
Amortization of intangible assets   231,000    247,000 
Amortization of other deferred costs   242,000    153,000 
Valuation adjustments   -    31,000 
Loss on exit of membership agreement   -    105,000 
Share-based compensation expense   1,122,000    575,000 
Benefit for accounts receivable allowance   (1,000)   (15,000)
Forgiveness of PPP Loan and accrued interest   (2,327,000)   - 
Benefit for income taxes   -    (733,000)
Changes in assets and liabilities   709,000    (876,000)
           
Net cash used in operating activities   (1,537,000)   (1,971,000)
           
Net cash from operating activities - discontinued operations   436,000    (2,374,000)
           
Cash flows used in investing activities:          
Capitalization of software development costs   (706,000)   (1,094,000)
Purchases of property and equipment   (3,000)   (34,000)
Proceeds from sale of ECM assets   800,000    11,288,000 
Net cash provided by investing activities   91,000    10,160,000 
           
Cash flows from financing activities:          
Proceeds from issuance of common stock   16,100,000    - 
Payments for costs directly attributable to the issuance of common stock   (1,318,000)   - 
Proceeds from term loan   -    2,301,000 
Principal payments on term loan   -    (4,000,000)
Other   (334,000)   (58,000)
Net cash provided by (used in) financing activities   14,448,000    (1,757,000)
Net increase in cash and cash equivalents   13,438,000    4,058,000 
Cash and cash equivalents at beginning of period   2,409,000    1,649,000 
Cash and cash equivalents at end of period  $15,847,000   $5,707,000 

 

 
 

 

STREAMLINE HEALTH SOLUTIONS, INC.

New Bookings

(Unaudited)

 

   July 31, 2021 
   Three Months
Ended
   Six Months
Ended
 
Software licenses  $-    135,000 
Professional Services   149,950    348,950 
Audit Services   21,800    407,800 
Maintenance and Support   -    135,000 
Software as a Service   1,455,000    3,180,000 
Q2 2021 Bookings  $1,626,750   $4,206,750 
Q2 2020 Bookings  $2,865,000   $4,150,000 

 

 
 

 

STREAMLINE HEALTH SOLUTIONS, INC.

Reconciliation of loss from continuing operations to non-GAAP Adjusted EBITDA

(in thousands)

(Unaudited)

 

   Three Months Ended July 31,   Six Months Ended July 31, 
   2021   2020   2021   2020 
Loss from continuing operations  $(71)  $(1,163)  $(2,534)  $(2,140)
Interest expense   9    13    22    27 
Income tax (benefit) expense   (4)   (172)   5    (733)
Depreciation   16    17    37    31 
Amortization of capitalized software development costs   478    362    984    651 
Amortization of intangible assets   116    124    231    247 
Amortization of other costs   126    78    242    153 
EBITDA   670    (741)   (1,013)   (1,764)
Share-based compensation expense   557    349    1,122    613 
Non-cash valuation adjustments   -    14    -    31 
Loss on exit of operating lease   -    -    -    105 
Other non-recurring operating expenses   336    -    793    - 
Forgiveness of PPP Loan and accrued interest   (2,327)   -    (2,327)   - 
Adjusted EBITDA  $(764)  $(378)  $(1,425)  $(1,015)
Adjusted EBITDA per diluted share:                    
Net loss per common share – diluted  $(0.00)  $(0.04)  $(0.05)  $0.08 
Adjusted EBITDA per adjusted diluted share  $(0.02)  $(0.01)  $(0.04)  $(0.03)
                     
Diluted weighted average shares   41,288,709    30,026,658    39,393,333    29,897,236 
Includable incremental shares — Adjusted EBITDA   448,522    394,815    567,665    332,359 
Adjusted diluted shares   41,737,231    30,421,473    39,960,998    30,229,595